Twist Bioscience (NASDAQ:TWST) Trading Up 8%

Twist Bioscience Co. (NASDAQ:TWST)’s stock price was up 8% on Tuesday . The stock traded as high as $31.81 and last traded at $31.81. Approximately 105,794 shares were traded during trading, a decline of 88% from the average daily volume of 907,955 shares. The stock had previously closed at $29.45.

Analyst Ratings Changes

A number of analysts recently weighed in on TWST shares. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Barclays reduced their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. Finally, Scotiabank raised their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a report on Monday, February 5th.

Twist Bioscience Price Performance

The stock has a 50 day moving average price of $35.26 and a two-hundred day moving average price of $30.22. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -8.81 and a beta of 1.62.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The firm had revenue of $71.50 million for the quarter, compared to analysts’ expectations of $67.59 million. During the same quarter in the prior year, the firm posted ($0.74) earnings per share. The company’s quarterly revenue was up 31.8% on a year-over-year basis. Sell-side analysts forecast that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, Director Robert Chess sold 4,110 shares of Twist Bioscience stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Robert Chess sold 4,110 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now directly owns 64,169 shares in the company, valued at $2,244,631.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,487 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the sale, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. Insiders have sold a total of 11,037 shares of company stock worth $384,092 in the last quarter. 3.92% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in the stock. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the 4th quarter worth approximately $30,000. Federated Hermes Inc. acquired a new position in Twist Bioscience in the 3rd quarter valued at about $29,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Twist Bioscience by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after purchasing an additional 1,179 shares during the period. Finally, International Assets Investment Management LLC grew its stake in Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after purchasing an additional 3,907 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.